Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.

[1]  B. Vennema,et al.  Social impact bonds , 2021, The Essentials of Social Finance.

[2]  A. Wade.  Can community pharmacists treat hepatitis C virus? , 2020, The Lancet Gastroenterology & Hepatology.

[3]  A. Slocum,et al.  Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine , 2020, Proceedings of the National Academy of Sciences.

[4]  M. van der Valk,et al.  Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C , 2020, BMJ open gastroenterology.

[5]  J. Seeley,et al.  Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis , 2020, PLoS medicine.

[6]  G. Macedo,et al.  Elimination of Hepatitis C in Portugal: An Urban Legend? , 2020, GE - Portuguese Journal of Gastroenterology.

[7]  Lai Wei,et al.  Management Algorithm for Interrupting Mother to Child Transmission of Hepatitis B Virus. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  K. Stone,et al.  The Global State of Harm Reduction in Prisons , 2019, Journal of correctional health care : the official journal of the National Commission on Correctional Health Care.

[9]  A. Dublineau,et al.  Field evaluation of GeneXpert® (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia , 2018, Journal of viral hepatitis.

[10]  F. Bray,et al.  The public health challenge of liver cancer in Mongolia. , 2018, The lancet. Gastroenterology & hepatology.

[11]  U. d’Alessandro,et al.  Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. , 2018, Journal of hepatology.

[12]  I. Waked,et al.  One step closer to elimination of hepatitis C in Egypt. , 2018, The lancet. Gastroenterology & hepatology.

[13]  B. Cowie,et al.  Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030 , 2018, Journal of gastroenterology and hepatology.

[14]  J. Lazarus,et al.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[15]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[16]  M. Bilodeau,et al.  The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver , 2018, Canadian Medical Association Journal.

[17]  J. Roy,et al.  Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study , 2018, Open forum infectious diseases.

[18]  G. Dore,et al.  Elimination of Hepatitis C Virus in Australia: Laying the Foundation. , 2018, Infectious disease clinics of North America.

[19]  J. Schrack,et al.  The Health of America’s Aging Prison Population , 2018, Epidemiologic reviews.

[20]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[21]  G. Dore,et al.  Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay , 2018, The Journal of infectious diseases.

[22]  S. Nsanzimana,et al.  Is hepatitis C elimination possible in sub-Saharan Africa? The case of Rwanda. , 2018, The lancet. Gastroenterology & hepatology.

[23]  J. Rockstroh.  Is Hepatitis C Virus Elimination in Well-Defined Patient Groups Possible? , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Boucher,et al.  Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Fontanet,et al.  Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus , 2018, Gut.

[26]  S. Murad,et al.  Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial , 2018 .

[27]  J. Richmond,et al.  Implementation of hepatitis C cure in Australia: one year on , 2018, Journal of virus eradication.

[28]  P. Hayes,et al.  Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis , 2018 .

[29]  A. Dublineau,et al.  Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia , 2018 .

[30]  J. Lazarus,et al.  Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe , 2018, Journal of viral hepatitis.

[31]  P. Read,et al.  Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.

[32]  L. Tavoschi,et al.  Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups , 2018, BMC Infectious Diseases.

[33]  J. Lazarus,et al.  Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. , 2018, The lancet. Gastroenterology & hepatology.

[34]  B. Cowie,et al.  Mapping progress in chronic hepatitis B: geographic variation in prevalence, diagnosis, monitoring and treatment, 2013–15 , 2018, Australian and New Zealand journal of public health.

[35]  J. Losa,et al.  Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant , 2018, Open forum infectious diseases.

[36]  I. Waked,et al.  Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. , 2017, Journal of hepatology.

[37]  Lanjuan Li,et al.  Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update) , 2017, Journal of clinical and translational hepatology.

[38]  R. Peeling,et al.  Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature , 2017, BMC Infectious Diseases.

[39]  R. Peeling,et al.  The future of viral hepatitis testing: innovations in testing technologies and approaches , 2017, BMC Infectious Diseases.

[40]  P. Easterbrook,et al.  Economic evaluation of HCV testing approaches in low and middle income countries , 2017, BMC Infectious Diseases.

[41]  Debrah I. Boeras,et al.  Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis , 2017, BMC Infectious Diseases.

[42]  P. Easterbrook,et al.  Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses , 2017, BMC Infectious Diseases.

[43]  P. Easterbrook,et al.  Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples – a systematic review and meta-analysis , 2017, BMC Infectious Diseases.

[44]  J. Leung,et al.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.

[45]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[46]  S. Asch,et al.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. , 2017, Gastroenterology.

[47]  M. Hellard,et al.  Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. , 2017, The International journal on drug policy.

[48]  G. Dore,et al.  Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. , 2017, The International journal on drug policy.

[49]  G. Dore,et al.  Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. , 2017, The International journal on drug policy.

[50]  H. Hagan,et al.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs , 2017, The Cochrane database of systematic reviews.

[51]  H. Masur,et al.  Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. , 2017, Annals of internal medicine.

[52]  J. Whitcomb,et al.  Geographic Disparities in Access to Syringe Services Programs Among Young Persons With Hepatitis C Virus Infection in the United States , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  L. Soto-Ramírez.  World hepatitis day. Fighting hepatitis C in Latin America and the Caribbean; an urgent call , 2017, Journal of the International AIDS Society.

[54]  A. Hogewoning,et al.  Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.

[55]  A. Hill,et al.  The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries , 2017, Journal of virus eradication.

[56]  R. Atun,et al.  Innovative financing instruments for global health 2002-15: a systematic analysis. , 2017, The Lancet. Global health.

[57]  G. Dore,et al.  Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. , 2017, The lancet. Gastroenterology & hepatology.

[58]  R. Tohme,et al.  The status of hepatitis B control in the African region , 2017, The Pan African medical journal.

[59]  S. Norris,et al.  Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response , 2017, PloS one.

[60]  Reed J. D. Sorensen,et al.  Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries , 2017, The Lancet.

[61]  J. George,et al.  Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis , 2017, Clinical and molecular hepatology.

[62]  G. Dore,et al.  HCV reinfection incidence among individuals treated for recent infection , 2017, Journal of viral hepatitis.

[63]  K. Lasser,et al.  A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home , 2017, The Annals of Family Medicine.

[64]  M. Manns,et al.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[65]  Xiaofeng Liang,et al.  Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China , 2017, Emerging infectious diseases.

[66]  Marcela Contreras,et al.  Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas , 2017, BMC Public Health.

[67]  I. Waked,et al.  National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care , 2017, Journal of viral hepatitis.

[68]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[69]  J. Mukherjee,et al.  “Waiting for DAAs”: A retrospective chart review of patients with untreated hepatitis C in Rwanda , 2017, PloS one.

[70]  S. Sarin,et al.  Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[71]  S. Alavian,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[72]  Jinfeng Liu,et al.  No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg , 2017, Infectious diseases.

[73]  M. Hickman,et al.  Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. , 2017, Addiction.

[74]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[75]  F. Laraque,et al.  From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  R. Chou,et al.  Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. , 2016, The Lancet. Infectious diseases.

[77]  T. Hallett,et al.  Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.

[78]  M. Alavi,et al.  Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). , 2016, Journal of hepatology.

[79]  T. Vos,et al.  Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. , 2016, The Lancet. Infectious diseases.

[80]  A. Lok,et al.  Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[81]  K. Stone.  Global state of harm reduction 2016. , 2016 .

[82]  S. Holmberg,et al.  Awareness of Infection and Medical Follow-Up Among persons Testing Positive for Hepatitis C Virus — National Health and Nutrition Examination Survey, 2001‒2014 , 2016 .

[83]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[84]  Eyal Oren,et al.  Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015 , 2016, Lancet.

[85]  P. Easterbrook,et al.  Hepatitis C: global epidemiology and strategies for control. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[86]  R. DeMarco,et al.  Knowledge and Attitudes toward HIV, Hepatitis B Virus, and Hepatitis C Virus Infection among Health-care Workers in Malawi , 2016, Asia-Pacific journal of oncology nursing.

[87]  J. Macías,et al.  HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.

[88]  P. Easterbrook.  Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. , 2016, Journal of hepatology.

[89]  G. Lau,et al.  A hepatitis B-free generation in China: from dream to reality. , 2016, The Lancet. Infectious diseases.

[90]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[91]  B. Moazen,et al.  Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners , 2016, The Lancet.

[92]  A. Vigani,et al.  Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic , 2016, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[93]  Mohamed O Ahmed,et al.  Hepatitis C Virus in North Africa: An Emerging Threat , 2016, TheScientificWorldJournal.

[94]  Xu Ma,et al.  Seroepidemiological survey of hepatitis B virus infection among 764,460 women of childbearing age in rural China: A cross-sectional study. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[95]  T. Hallett,et al.  Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. , 2016, The Lancet. Global health.

[96]  H. Whittle,et al.  Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. , 2016, The Lancet. Global health.

[97]  J. Cairns,et al.  Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.

[98]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[99]  K. Leder,et al.  An overview of the epidemiology of notifiable infectious diseases in Australia, 1991–2011 , 2016, Epidemiology and Infection.

[100]  Shuqin Zhang,et al.  Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.

[101]  J. Layden,et al.  A Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000–2013 , 2016, BMC Infectious Diseases.

[102]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[103]  Xi Li,et al.  Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. , 2016, Vaccine.

[104]  M. Hellard,et al.  The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? , 2016, PloS one.

[105]  M. Hellard,et al.  A systematic review of community based hepatitis C treatment , 2016, BMC Infectious Diseases.

[106]  J. Ward,et al.  Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection - Cherokee Nation, 2012-2015. , 2016, MMWR. Morbidity and mortality weekly report.

[107]  Z. Konopski,et al.  Hepatitis C reinfection after sustained virological response. , 2016, Journal of hepatology.

[108]  K. Owusu-Edusei,et al.  Cost‐effectiveness of active‐passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection , 2016, Hepatology.

[109]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[110]  M. Hellard,et al.  Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model , 2016, Gut.

[111]  P. Gow,et al.  Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed , 2016, Hepatology.

[112]  C. Beyrer,et al.  Public health and international drug policy , 2016, The Lancet.

[113]  Carla V. Rodriguez,et al.  Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  P. Angus,et al.  The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand , 2016, Journal of gastroenterology and hepatology.

[115]  L. Nguyen,et al.  Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation , 2016, Digestive Diseases and Sciences.

[116]  Chris Mccall.  Australia commits funds to curb hepatitis C epidemic , 2016, The Lancet.

[117]  R. Riley,et al.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  J. Grefenstette,et al.  Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons , 2016, Annals of Internal Medicine.

[119]  Bryony Simmons,et al.  Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C , 2016, Journal of virus eradication.

[120]  M. Shiffman.  Universal screening for chronic hepatitis C virus , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[121]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[122]  H. Jones,et al.  Problem drug use prevalence estimation revisited: heterogeneity in capture–recapture and the role of external evidence , 2015, Addiction.

[123]  J. Montaner,et al.  Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? , 2015, PloS one.

[124]  B. Cowie,et al.  Improving the identification of priority populations to increase hepatitis B testing rates, 2012 , 2015, BMC Public Health.

[125]  M. Hellard,et al.  The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service , 2015, PloS one.

[126]  S. Hamid,et al.  Disparity in market prices for hepatitis C virus direct-acting drugs. , 2015, The Lancet. Global health.

[127]  R. Mikolajczyk,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[128]  G. Dore,et al.  Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. , 2015, The International journal on drug policy.

[129]  M. Plummer,et al.  World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.

[130]  P. Msaouel,et al.  Improving Hepatitis C Virus Screening Rates in Primary Care: A Targeted Intervention Using the Electronic Health Record , 2015, Journal for healthcare quality : official publication of the National Association for Healthcare Quality.

[131]  G. Dore,et al.  The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention , 2015, Current opinion in HIV and AIDS.

[132]  G. Dore,et al.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.

[133]  C. Thio,et al.  Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. , 2015, The Lancet. Infectious diseases.

[134]  H. Whittle,et al.  Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia , 2015, Gut.

[135]  N. Ford,et al.  Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis. , 2015, The Lancet. Infectious diseases.

[136]  G. Cooke,et al.  The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa , 2015, Gut.

[137]  H. Razavi,et al.  Disease burden of chronic hepatitis C in Brazil , 2015, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[138]  B. Cowie,et al.  The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment , 2015, Australian and New Zealand journal of public health.

[139]  G. Cooke,et al.  Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries , 2015, Journal of virus eradication.

[140]  H. Razavi,et al.  P1263 : Global estimate of HCV infection in the pediatric and adolescent population , 2015 .

[141]  L. Abu-Raddad,et al.  The Epidemiology of Hepatitis C Virus in the Maghreb Region: Systematic Review and Meta-Analyses , 2015, PloS one.

[142]  N. Ford,et al.  Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus , 2015, Hepatology.

[143]  M. Abdel-hamid,et al.  Hepatitis C virus acquisition among Egyptians: analysis of a 10‐year surveillance of acute hepatitis C , 2015, Tropical medicine & international health : TM & IH.

[144]  P. Pattison,et al.  The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs , 2014, Hepatology.

[145]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[146]  M. Hellard,et al.  An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories , 2014, Journal of gastroenterology and hepatology.

[147]  G. Lauer,et al.  A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. , 2014, Journal of hepatology.

[148]  S. Kerns,et al.  Social impact bonds: behavioral health opportunities. , 2014, JAMA pediatrics.

[149]  B. Mayosi,et al.  Health and health care in South Africa--20 years after Mandela. , 2014, The New England journal of medicine.

[150]  A. Mocroft,et al.  HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective , 2014, BMC Infectious Diseases.

[151]  J. Lazarus,et al.  Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey , 2014, BMC Infectious Diseases.

[152]  D. Sahota,et al.  Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China , 2014, Bulletin of the World Health Organization.

[153]  H. Razavi,et al.  Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C‐related liver disease and costs in Australia , 2014, Journal of gastroenterology and hepatology.

[154]  A. Bjork,et al.  Progress Toward Prevention of Transfusion-Transmitted Hepatitis B and Hepatitis C Infection — Sub-Saharan Africa, 2000–2011 , 2014, MMWR. Morbidity and mortality weekly report.

[155]  C. Umscheid,et al.  The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis , 2014, PloS one.

[156]  L. Abu-Raddad,et al.  Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[157]  L. Valiquette,et al.  Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010 , 2014, PloS one.

[158]  H. Razavi,et al.  The current and future disease burden of chronic hepatitis C virus infection in Egypt. , 2014, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[159]  R. Dhiman.  Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? , 2014, Journal of clinical and experimental hepatology.

[160]  R. Aggarwal,et al.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. , 2014, Journal of clinical and experimental hepatology.

[161]  J. Ward,et al.  Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward) , 2014, Journal of viral hepatitis.

[162]  E. Akl,et al.  WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. , 2014, The International journal on drug policy.

[163]  E. Nelson,et al.  Hepatitis C testing and status among opioid substitution treatment clients in New South Wales , 2014, Australian and New Zealand journal of public health.

[164]  N. Marwaha,et al.  Current testing strategies for hepatitis C virus infection in blood donors and the way forward. , 2014, World journal of gastroenterology.

[165]  J. Ward,et al.  Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 , 2014, Annals of Internal Medicine.

[166]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[167]  S. Hutchinson,et al.  Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross‐sectional survey data , 2014, Journal of viral hepatitis.

[168]  S. Hadler,et al.  Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project. , 2013, Vaccine.

[169]  L. Gorgos.  Sexual transmission of viral hepatitis. , 2013, Infectious disease clinics of North America.

[170]  B. Hajarizadeh,et al.  Challenges in managing patients in Australia with chronic hepatitis B: the General Practitioners’ perspective , 2013, Australian and New Zealand journal of public health.

[171]  M. Lai,et al.  Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. , 2013, JAMA.

[172]  B. Cowie,et al.  Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis , 2013, BMC Infectious Diseases.

[173]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[174]  O. Pybus,et al.  Infection Frequency of Hepatitis C Virus and IL28B Haplotypes in Papua New Guinea, Fiji, and Kiribati , 2013, PloS one.

[175]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[176]  M. Hellard,et al.  Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[177]  A. Hall,et al.  Association of Early Age at Establishment of Chronic Hepatitis B Infection with Persistent Viral Replication, Liver Cirrhosis and Hepatocellular Carcinoma: A Systematic Review , 2013, PloS one.

[178]  J. Jia,et al.  Update on epidemiology of hepatitis B and C in China , 2013, Journal of gastroenterology and hepatology.

[179]  K. Choi,et al.  Determinants of suboptimal hepatitis B vaccine uptake among men in the Republic of Korea: where should our efforts be focused: results from cross-sectional study , 2013, BMC Infectious Diseases.

[180]  A. Altaf,et al.  Lessons learned from a community based intervention to improve injection safety in Pakistan , 2013, BMC Research Notes.

[181]  M. Salminen,et al.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening , 2013, BMC Infectious Diseases.

[182]  A. Lloyd,et al.  Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[183]  M. Hellard,et al.  Current and emerging antiviral treatments for hepatitis C infection , 2013, British journal of clinical pharmacology.

[184]  S. Laperche.  Multinational assessment of blood‐borne virus testing and transfusion safety on the African continent , 2013, Transfusion.

[185]  M. Turchi,et al.  Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study , 2013, BMC Infectious Diseases.

[186]  S. Hamid,et al.  Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries , 2013, Hepatology International.

[187]  R. Atun,et al.  Innovative financing for health: what is truly innovative? , 2012, The Lancet.

[188]  J. Dehovitz,et al.  Occupational exposure to body fluids among health care workers in Georgia. , 2012, Occupational medicine.

[189]  F. Sanai,et al.  Epidemiology of Viral Hepatitis in Saudi Arabia: Are We Off the Hook? , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[190]  P. Vickerman,et al.  Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. , 2012, Addiction.

[191]  Youxin Wang,et al.  Prevalence and Factors Associated with Hepatitis B Immunization and Infection among Men Who Have Sex with Men in Beijing, China , 2012, PloS one.

[192]  N. Pai,et al.  Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review , 2012, Sexually Transmitted Infections.

[193]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[194]  A. Spaulding,et al.  Screening for HCV infection in jails. , 2012, JAMA.

[195]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[196]  J. Kobayashi,et al.  The relevance of Japan's hepatitis vaccine policy to national Hepatitis B prevention and control , 2012, Journal of public health policy.

[197]  A. Wasley,et al.  The Increasing Burden of Imported Chronic Hepatitis B — United States, 1974–2008 , 2011, PloS one.

[198]  A. Barros,et al.  Towards universal health coverage: the role of within-country wealth-related inequality in 28 countries in sub-Saharan Africa. , 2011, Bulletin of the World Health Organization.

[199]  C. Weinbaum,et al.  Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009. , 2011, Vaccine.

[200]  B. McMahon,et al.  Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch‐up immunization program , 2011, Hepatology.

[201]  B. Cowie,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[202]  Sanjeev Arora,et al.  Outcomes of treatment for hepatitis C virus infection by primary care providers. , 2011, The New England journal of medicine.

[203]  D. Vlahov,et al.  Changes in blood-borne infection risk among injection drug users. , 2011, The Journal of infectious diseases.

[204]  H. Whittle,et al.  Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[205]  R. Atun,et al.  Universal access to malaria medicines: innovation in financing and delivery , 2010, The Lancet.

[206]  Sanjeev Arora,et al.  Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care , 2010, Hepatology.

[207]  T. Rhodes,et al.  Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. , 2010, Addiction.

[208]  A. Tandon,et al.  Assessing public expenditure on health from a fiscal space perspective , 2010 .

[209]  J. Kaldor,et al.  Incidence and risk for acute hepatitis C infection during imprisonment in Australia , 2010, European Journal of Epidemiology.

[210]  B. Bell,et al.  Impact of Routine Hepatitis B Immunization on the Prevalence of Chronic Hepatitis B Virus Infection in the Marshall Islands and the Federated States of Micronesia , 2010, The Pediatric infectious disease journal.

[211]  A. Hall,et al.  Hepatitis B treatment in resource poor settings: time for action , 2009, Tropical medicine & international health : TM & IH.

[212]  M. Abdel-hamid,et al.  Injection Drug Use Is a Risk Factor for HCV Infection in Urban Egypt , 2009, PloS one.

[213]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[214]  R. Atun,et al.  Innovating for impact: The Affordable Medicines Facility-malaria (AMFm) , 2009, Nature Medicine.

[215]  N. Danielsson,et al.  Improved immunization practices reduce childhood hepatitis B infection in Tonga. , 2009, Vaccine.

[216]  L. Dickinson,et al.  Physician practices regarding adult hepatitis B vaccination: a national survey. , 2009, American journal of preventive medicine.

[217]  S. Saab,et al.  Viral Hepatitis in Incarcerated Adults: A Medical and Public Health Concern , 2009, The American Journal of Gastroenterology.

[218]  Y. Kinfu,et al.  The health worker shortage in Africa: are enough physicians and nurses being trained? , 2009, Bulletin of the World Health Organization.

[219]  M. Mahtab,et al.  Epidemiology of hepatitis B virus in Bangladeshi general population. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.

[220]  A. Abdo,et al.  Long-term protection of hepatitis B vaccine 18 years after vaccination. , 2008, The Journal of infection.

[221]  L. Wen,et al.  Low knowledge and high infection rates of hepatitis in Vietnamese men in Sydney. , 2008, Sexual health.

[222]  G. Rezza,et al.  Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis , 2008, Journal of Epidemiology & Community Health.

[223]  N. Van Cuong,et al.  Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. , 2008, Vaccine.

[224]  R. Guy,et al.  Barriers to the delivery of the hepatitis B birth dose: a study of five Papua New Guinean hospitals in 2007. , 2008, Papua and New Guinea medical journal.

[225]  F. P. De la Hoz,et al.  Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[226]  A. Sutanto,et al.  Implementing the birth dose of hepatitis B vaccine in rural Indonesia. , 2007, Vaccine.

[227]  J. Elmore,et al.  Release from prison--a high risk of death for former inmates. , 2007, The New England journal of medicine.

[228]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[229]  Colin W Shepard,et al.  Hepatitis B virus infection: epidemiology and vaccination. , 2006, Epidemiologic reviews.

[230]  P. Heller.  The prospects of creating 'fiscal space' for the health sector. , 2006, Health policy and planning.

[231]  中华医学会肝病学分会、感染病学分会.  The guideline of prevention and treatment for chronic hepatitis B , 2005 .

[232]  Fangjun Zhou,et al.  A mathematical model to estimate global hepatitis B disease burden and vaccination impact. , 2005, International journal of epidemiology.

[233]  Akira Igarashi,et al.  Comparison of clinical features and hematologic abnormalities between dengue fever and dengue hemorrhagic fever among children in the Philippines. , 2005, The American journal of tropical medicine and hygiene.

[234]  C. Bullen,et al.  The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. , 2005, The New Zealand medical journal.

[235]  P. Heller.  Understanding Fiscal Space , 2005, IMF Policy Discussion Papers.

[236]  D. Skowronski,et al.  Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students , 2003, The Pediatric infectious disease journal.

[237]  Y. Buisson,et al.  10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia). , 2003, Vaccine.

[238]  B. Stewart,et al.  World Cancer Report , 2003 .

[239]  Malla R Rao,et al.  Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt , 2002, BMC infectious diseases.

[240]  P. van Damme,et al.  Hepatitis B vaccination: how to reach risk groups. , 2002, Vaccine.

[241]  A. Dev,et al.  A survey of Australian general practice management of hepatitis C‐infected patients from non‐English‐speaking backgrounds , 2002, Journal of gastroenterology and hepatology.

[242]  A. Bradford.  The Australian Immunisation Handbook , 2000 .

[243]  E. Gotuzzo,et al.  [IMPACT OF THE IMMUNIZATION PROGRAM INTEGRATED TO THE EXPANDED IMMUNIZATION PROGRAM(EPI) IN HUANTA,1994-1997] , 2000, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[244]  N. Wilson,et al.  The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. , 2000, Vaccine.

[245]  L. Magder,et al.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.

[246]  A. Al-Swailem,et al.  Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. , 1999, The Journal of infection.

[247]  Kathy Robertson,et al.  The European Monitoring Centre for Drugs and Drug Addiction , 1998 .

[248]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[249]  A. Milne,et al.  Kawerau revisited: hepatitis A and B seroprevalence in 1984 and 1993. , 1994, The New Zealand medical journal.

[250]  A J Hall,et al.  The influence of age on the development of the hepatitis B carrier state , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[251]  D. Vergani,et al.  Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? , 1990, The Lancet.

[252]  F. Al-Faleh.  Hepatitis B Infection in Saudi Arabia , 1988 .

[253]  B. McMahon,et al.  The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. , 1985, American journal of epidemiology.

[254]  R. Koff,et al.  Contagiousness of acute hepatitis B. Secondary attack rates in household contacts. , 1977, Gastroenterology.

[255]  THE WORLD HEALTH ORGANIZATION , 1954 .

[256]  H. Ten Have,et al.  Global Fund , 2021, Dictionary of Global Bioethics.

[257]  M. Dickie,et al.  Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .

[258]  Brian L. Strom,et al.  A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report , 2017 .

[259]  S. Katz,et al.  Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study , 2017 .

[260]  R. Mikolajczyk,et al.  Time trends of chronic HBV infection over prior decades - A global analysis. , 2017, Journal of hepatology.

[261]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[262]  P. Hayes,et al.  Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort , 2017 .

[263]  Hepatitis B vaccines: WHO position paper – July 2017. , 2017, Releve epidemiologique hebdomadaire.

[264]  A. W. Lin,et al.  Surveillance and response of hepatitis B virus in Hong Kong Special Administrative Region, 1988-2014. , 2016, Western Pacific surveillance and response journal : WPSAR.

[265]  I. Waked,et al.  Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis , 2016 .

[266]  F. Souto.  Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21 st century. , 2016, Revista da Sociedade Brasileira de Medicina Tropical.

[267]  T. Vos,et al.  Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C and hepatitis B: findings from the Global Burden of Disease Study , 2016 .

[268]  Keat Hong Lee,et al.  Reimbursement policies in the Asia-Pacific for chronic hepatitis B , 2014, Hepatology International.

[269]  A. Pharris,et al.  Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.

[270]  C. Beyrer,et al.  What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. , 2014, The International journal on drug policy.

[271]  D. Pasta.  Hepatitis C virus acquisition among Egyptians : analysis of a 10-year surveillance of acute hepatitis , 2014 .

[272]  F. Abaalkhail,et al.  SASLT Practice Guidelines for the Management of Hepatitis B Virus , 2014, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[273]  B. Stewart,et al.  World cancer report 2014. , 2014 .

[274]  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.

[275]  C. Elias,et al.  Global Vaccine Action Plan 2011-2020. , 2013 .

[276]  F. Carrilho,et al.  Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. , 2013, Antiviral therapy.

[277]  G. Esmat,et al.  Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. , 2012, MMWR. Morbidity and mortality weekly report.

[278]  S. Ray,et al.  Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. , 2010, Gastroenterology.

[279]  Norman Gitlin,et al.  Chronic hepatitis B : an update , 2010 .

[280]  S. Vermund,et al.  Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[281]  M. Rani,et al.  Policy & practice Hepatitis B control by 2012 in the WHO Western Pacific Region : rationale and implications , 2009 .

[282]  Organización Mundial de la Salud.  Home visits for the newborn child: a strategy to improve survival , 2009 .

[283]  S. Nick,et al.  Evaluation of 17 CE‐marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection , 2006, Journal of medical virology.

[284]  J. Kaldor,et al.  Prisoners are at risk for hepatitis C transmission , 2004, European Journal of Epidemiology.

[285]  J. McCormick,et al.  Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. , 2000, Bulletin of the World Health Organization.

[286]  I. Gust.  Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. , 1996, Gut.

[287]  J. Roux,et al.  [Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine]. , 1996, Sante.

[288]  E. Somers.  International Agency for Research on Cancer. , 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[289]  Hepatitis A vaccines WHO position paper , 2022 .